Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab

Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ

Arthritis Rheum · 2011

Grade Dcase reportn=1Verified
DOI ↗PubMed ↗

Key Findings

  • ●First case report of tocilizumab in TRAPS
  • ●Effective when etanercept and anakinra had failed
  • ●Supports role of IL-6 in TRAPS pathogenesis

Referenced in (1 disease)

TNF Receptor-Associated Periodic Syndrome

Validation history

Full log →
  1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

    Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

    tools: pubmed.esummary, crossref.works

ID: pmid-21225679DOI: 10.1002/art.30215PMID: 21225679